Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus Chemotherapy in Chinese Patients with Recurrent and/or Metastatic SCCHN
NCT02383966Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Progression-free Survival (IRC) up to 904 days. Started Jul 2015; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02383966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383966.